Doxorubicin in combination with a small TGFβ inhibitor: A potential novel therapy for metastatic breast cancer in mouse models

PLoS ONE

Volumn 5, Issue 4, 2010, Pages

  Bandyopadhyay, Abhik ^a   Wang, Long ^a   Agyin, Joseph ^b   Tang, Yuping ^a   Lin, Shu ^a   Yeh, I Tien ^a   De, Keya ^a   Sun, Lu Zhe ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PLACEBO; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CANCER STEM CELL; CELL INVASION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EPITHELIUM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; LUNG METASTASIS; MESENCHYME; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; BREAST TUMOR; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DOXORUBICIN; HUMANS; LUNG NEOPLASMS; MAMMARY NEOPLASMS, ANIMAL; MICE; NEOPLASM METASTASIS; NEOPLASMS, EXPERIMENTAL; TRANSFORMING GROWTH FACTOR BETA; TRANSPLANTATION, HETEROLOGOUS;

EID: 77953765387     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010365     Document Type: Article

References (56)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108.
2. Gamucci T, D'Ottavio AM, Magnolfi E, Barduagni M, Vaccaro A, et al. (2007) Weekly epirubicin plus docetaxel as first-line treatment in metastatic breast cancer. Br J Cancer 97: 1040-1045.
3. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, et al. (2003) Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592.
4. Ellis MJ, Hayes DF, Lippman ML (2004) Treatment of metastatic breast cancer: Diseases of the breast 3rd: 749-797.
5. Chen JH, Ling R, Yao Q, Li Y, Chen T, et al. (2005) Effect of small-sized liposomal Adriamycin administered by various routes on a metastatic breast cancer model. Endocr Relat Cancer 12: 93-100.
6. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA (1992) Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res 52: 6949-6952.
7. Walker RA, Gallacher B (1995) Determination of transforming growth factor beta 1 mRNA expression in breast carcinomas by in situ hybridization. J Pathol 177: 123-127.
8. Tang BW, Vu M, Booker T, Santner SJ, Miller FR, et al. (2003) TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. Journal of Clinical Investigation 112: 1116-1124.
9. Ivanovic V, Todorovic-Rakovic N, Demajo M, Neskovic-Konstantinovic Z, Subota V, et al. (2003) Elevated plasma levels of transforming growth factor beta(1) (TGF-beta(1)) in patients with advanced breast cancer: association with disease progression. European Journal of Cancer 39: 454-461.
10. Dalal BI, Keown PA, Greenberg AH (1993) Immunocytochemical localization of secreted transforming growth factor-beta 1 to the advancing edges of primary tumors and to lymph node metastases of human mammary carcinoma. Am J Pathol 143: 381-389.
11. Verona EV, Elkahloun AG, Yang J, Bandyopadhyay A, Yeh IT, et al. (2007) Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res 67: 5737-5746.
12. Wikström P, Stattin P, Franck-Lissbrant I, Damber JE, Bergh A (1998) Transforming growth factor b1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate 37: 19-29.
13. Sosroseno W, Herminajeng E (1995) The immunoregulatory roles of transforming growth factor beta. Br J Biomed Sci 52: 142-148.
14. Lei XF, Bandyopadhyay A, Le T, Sun LZ (2002) Autocrine TGF beta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 21: 7514-7523.
15. Lei X, Yang J, Nichols RW, Sun LZ (2007) Abrogation of TGFbeta signaling induces apoptosis through the modulation of MAP kinase pathways in breast cancer cells. Exp Cell Res 313: 1687-1695.
16. Arteaga CL (2006) Inhibition of TGFbeta signaling in cancer therapy. Curr Opin Genet Dev 16: 30-37.
17. Sun L (2004) Tumor-suppressive and promoting function of transforming growth factor beta. Front Biosci 9: 1925-1935.
18. Yingling JM, Blanchard KL, Sawyer JS (2004) Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3: 1011-1022.
19. Bandyopadhyay A, Sun L-Z (2008) Soluble TGF beta Type III Receptor Suppresses Malignant Progression of Human Cancer Cells. Cancer Drug Discovery and Development: ransforming Growth Factor-beta in Cancer Therapy, Vol 2: Cancer Treatment and Therapy. pp 723-735.
20. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, et al. (2006) Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25: 3408-3423.
21. Ehata S, Hanyu A, Fujime M, Katsuno Y, Fukunaga E, et al. (2007) Ki26894, a novel transforming growth factor-beta type I receptor kinase inhibitor, inhibits in vitro invasion and in vivo bone metastasis of a human breast cancer cell line. Cancer Sci 98: 127-133.
22. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, et al. (2006) Inhibition of Pulmonary and Skeletal Metastasis by a Transforming Growth Factor-{beta} Type I Receptor Kinase Inhibitor. Cancer Res 66: 6714-6721.
23. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, et al. (2006) Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res 12: 4315-4330.
24. Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, et al. (2007) A Novel Small-Molecule Inhibitor of Transforming Growth Factor {beta} Type I Receptor Kinase (SM16) Inhibits Murine Mesothelioma Tumor Growth In vivo and Prevents Tumor Recurrence after Surgical Resection. Cancer Res 67: 2351-2359.
25. Ehata S, Hanyu A, Hayashi M, Aburatani H, Kato Y, et al. (2007) Transforming Growth Factor-{beta} Promotes Survival of Mammary Carcinoma Cells through Induction of Antiapoptotic Transcription Factor DEC1. Cancer Res 67: 9694-9703.
26. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
27. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 3: e2888.
28. Shipitsin M, Campbell LL, Argani P, Weremowicz S, Bloushtain-Qimron N, et al. (2007) Molecular definition of breast tumor heterogeneity. Cancer Cell 11: 259-273.
29. Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D (1997) Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 11: 453-461.
30. Liu P, Menon K, Alvarez E, Lu K, Teicher BA (2000) Transforming growth factor-beta and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol 16: 599-610.
31. Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS (1997) Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 11: 463-472.
32. Biswas S, Guix M, Rinehart C, Dugger TC, Chytil A, et al. (2007) Inhibition of TGF-beta with neutralizing antibodies prevents radiation-induced acceleration of metastatic cancer progression. J Clin Invest 117: 1305-1313.
33. Hollier BG, Evans K, Mani SA (2009) The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies. J Mammary Gland Biol Neoplasia 14: 29-43.
34. Wu Y, Zhou BP (2008) New insights of epithelial-mesenchymal transition in cancer metastasis. Acta Biochim Biophys Sin (Shanghai) 40: 643-650.
35. Xu J, Lamouille S, Derynck R (2009) TGF-beta-induced epithelial to mesenchymal transition. Cell Res 19: 156-172.
36. Medici D, Hay ED, Goodenough DA (2006) Cooperation between snail and LEF-1 transcription factors is essential for TGF-beta1-induced epithelialmesenchymal transition. Mol Biol Cell 17: 1871-1879.
37. Welm BE, Tepera SB, Venezia T, Graubert TA, Rosen JM, et al. (2002) Sca-1(pos) cells in the mouse mammary gland represent an enriched progenitor cell population. Dev Biol 245: 42-56.
38. Dean M (2009) ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 14: 3-9.
39. Dontu G, Wicha MS (2005) Survival of mammary stem cells in suspension culture: implications for stem cell biology and neoplasia. J Mammary Gland Biol Neoplasia 10: 75-86.
40. Grimshaw MJ, Cooper L, Papazisis K, Coleman JA, Bohnenkamp HR, et al. (2008) Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 10: R52.
41. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, et al. (2000) Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 88: 2979-2988.
42. Nikolic-Vukosavljevic D, Todorovic-Rakovic N, Demajo M, Ivanovic V, Neskovic B, et al. (2004) Plasma TGF-beta1-related survival of postmenopausal metastatic breast cancer patients. Clin Exp Metastasis 21: 581-585.
43. Tsushima H, Ito N, Tamura S, Matsuda Y, Inada M, et al. (2001) Circulating transforming growth factor beta 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 7: 1258-1262.
44. Charafe-Jauffret E, Monville F, Ginestier C, Dontu G, Birnbaum D, et al. (2008) Cancer stem cells in breast: current opinion and future challenges. Pathobiology 75: 75-84.
45. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, et al. (2009) Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 69: 1302-1313.
46. Davies JA (1996) Mesenchyme to epithelium transition during development of the mammalian kidney tubule. Acta Anat (Basel) 156: 187-201.
47. Planchard D, Soria JC, Michiels S, Grunenwald D, Validire P, et al. (2004) Uncertain benefit from surgery in patients with lung metastases from breast carcinoma. Cancer 100: 28-35.
48. Kolodziejski L, Goralczyk J, Dyczek S, Duda K, Dymek H, et al. (1999) [Analysis of indications and results of surgical treatment for patients with pulmonary metastasis]. Pneumonol Alergol Pol 67: 228-236.
49. Bandyopadhyay A, Lopez-Casillas F, Malik SN, Montiel JL, Mendoza V, et al. (2002) Antitumor Activity of a Recombinant Soluble Betaglycan in Human Breast Cancer Xenograft. Cancer Res 62: 4690-4695.
50. Muraoka-Cook RS, Kurokawa H, Koh Y, Forbes JT, Roebuck LR, et al. (2004) Conditional overexpression of active transforming growth factor beta1 in vivo accelerates metastases of transgenic mammary tumors. Cancer Res 64: 9002-9011.
51. Kakonen SM, Mundy GR (2003) Mechanisms of osteolytic bone metastases in breast carcinoma. Cancer 97: 834-839.
52. Martin TJ, Moseley JM (2000) Mechanisms in the skeletal complications of breast cancer. Endocr Relat Cancer 7: 271-284.
53. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, et al. (2005) A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 353: 793-802.
54. Sun L, Chen C (1997) Expression of transforming growth factor beta type III receptor suppresses tumorigenicity of human breast cancer MDA-MB-231 cells. J Biol Chem 272: 25367-25372.
55. Sawyer JS, Anderson BD, Beight DW, Campbell RM, Jones ML, et al. (2003) Synthesis and activity of new aryl-and heteroaryl- substituted pyrazole inhibitors of the transforming growth factor-b type I receptor kinase domain. Journal of Medicinal Chemistry 46: 3953-3956.
56. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, et al. (2003) Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg Med Chem Lett 13: 4355-4359.